Booker Slams Drug Companies For Not Lowering Prices Following Tax Law

April 10, 2018
Sen. Cory Booker (D-NJ) is criticizing drug companies for not using savings from the newly enacted tax law to lower drug prices. The senator, in a report released Monday (April 9), argued that companies are instead using their savings to buy back stocks and reward big investors. But while pharma buybacks have been substantial, the report reveals that only five of the 10 top drug companies have conducted buybacks. “Not a single company has forecast lowering prescription drug prices as...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.